RxDoctor Payments Data

Joseph Walsh, MD

Interventional Cardiology · Boise, IDNPI 1063674505

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (38.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Edwards Lifesciences accounts for 78.8% of it on its own, with 13 other manufacturers making up the rest. Among interventional cardiology clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$115,062in general payments, 2019–2025

Across 413 payments — averaging $278.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$91K
  • Abbott$8K
  • Shockwave Medical, Inc$7K
  • Abiomed$4K
  • Boston Scientific$4K
  • Medtronic$357
  • plus $645 from 8 others
$519,704in research payments, 2019–2025

Across 23 payments — averaging $22,596 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Edwards Lifesciences$488K
  • Abbott$32K

What the payments were for

  • Consulting fees$44,59439%
  • Speaking & faculty fees$37,86533%
  • Travel & lodging$18,76316%
  • Food & beverage$13,84012%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$115,062 in reported general payments places this provider in the 95th percentile of 29 interventional cardiology providers in Idaho.

See all interventional cardiology providers in Idaho

Medicare billing

Part B allowed, 2024
$169,438
Medicare patients
569
Services billed
1,366

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban16$14,572
Metoprolol Succinate24$506
Atorvastatin Calcium32$216
Carvedilol23$191
Rosuvastatin Calcium12$179
ClopidogrelClopidogrel Bisulfate21$155
Lisinopril13$55

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Boise

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →